This interview with a US-based key opinion leader (KOL) offers comprehensive insights into current disease landscape for spinal muscular atrophy (SMA) patients, and expectations regarding emerging pipeline therapies. The discussion covers the current treatment paradigm, as well as perspectives on the myostatin-targeted class and its prospective roles in future disease management. Key assets highlighted include Evrysdi, Spinraza, Zolgensma, apitegromab, taldefgrobep alfa, and GYM329.

This interview was conducted on 07 October 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.